TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16647152

Group type: EXPERIMENTAL
Intervention: Post-mastectomy radiotherapy (RT)
Number of subjects: 3083

Group type: EXPERIMENTAL
Intervention: Combined treatment with surgery and RT at the time of LRR
Number of subjects: 3083

Group type: COMPARATOR
Intervention: Surgery or RT alone
Number of subjects: 3083

Group type: COMPARATOR
Intervention: Initial randomization group
Number of subjects: 3083
Study: 12839215

Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridoxyliden‐aminoguanidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridoxal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pyridoxyliden‐aminoguanidine (PAG)
Number of subjects: 0
Study: 11005605

Group type: EXPERIMENTAL
Intervention: NIRS monitoring during CPB
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NIRS monitoring in the oxygenation study
Number of subjects: 41

Group type: COMPARATOR
Intervention: NIRS monitoring during DHCA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NIRS monitoring during validation study
Number of subjects: 41
Study: 14688947

Group type: COMPARATOR
Intervention: Single phototherapy (N=43)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Double phototherapy (N=37)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups (Single and Double phototherapy)
Number of subjects: 80
Study: 1728203

Group type: EXPERIMENTAL
Intervention: Dobutamine (0.38 mg/kg body weight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adenosine (0.84 mg/kg body weight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.84 mg/kg body weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 3968295

Group type: EXPERIMENTAL
Intervention: Isoproterenol at 2 micrograms . min‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isoproterenol at 4 micrograms . min‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dopamine at 200 micrograms . min‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dopamine at 400 micrograms . min‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dobutamine at 250 micrograms . min‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dobutamine at 500 micrograms . min‐1
Number of subjects: 12
Study: 31499528

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) (0.625 mg/d)
Number of subjects: 9939

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9939
Study: 30039171

Group type: EXPERIMENTAL
Intervention: Sudden wean from nCPAP
Number of subjects: 372

Group type: COMPARATOR
Intervention: Pressure wean from nCPAP
Number of subjects: 372
Study: 27091036

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori standard treatment for two weeks followed by antacid medication (morning and night) for three months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Antacid medication (morning and night) for four weeks followed by three months of antacid treatment
Number of subjects: 120
Study: 25374219

Group type: EXPERIMENTAL
Intervention: Hyperglycemia group (fasting glucose≥126 mg/dl and/or random blood glucose≥200 mg/dl)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Euglycemia group (normal blood glucose values)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Hyperglycemia group
Number of subjects: 159

Group type: COMPARATOR
Intervention: Euglycemia group
Number of subjects: 159
Study: 23364032

Group type: EXPERIMENTAL
Intervention: Case-based small group learning program, once a week for 5 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 69
Study: 20443023

Group type: EXPERIMENTAL
Intervention: High stretch loads during lateral jumps
Number of subjects: 9
Study: 17653959

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with 2 mg 17beta-estradiol/10 mg dydrogesterone (Femoston) for seven 28-day cycles
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16563251

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Celecoxib (10 micromol/L)
Number of subjects: 40
Study: 11867945

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 30
Study: 10087460

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline (Respicur retard(R) 400 mg) therapy
Number of subjects: 0
Study: 7754404

Group type: EXPERIMENTAL
Intervention: Continuous cryotherapy (Polar Care Model 500)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent cryotherapy (standard therapy with cool packs)
Number of subjects: 40
Study: 2181915

Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid (40 mg/kg/day in 3 or 4 divided doses)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Erythromycin-sulfisoxazole (Pediazole, 50 mg/kg/day in 3 divided doses)
Number of subjects: 111
Study: 534604

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol (800 microgram/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups (betamethasone and control)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Oral candidiasis
Number of subjects: 81
Study: 30125346

Group type: EXPERIMENTAL
Intervention: HPV-mRNA (Aptima, Hologic)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: HPV-DNA (Cobas 4800, Roche)
Number of subjects: 1204
Study: 27762489

Group type: EXPERIMENTAL
Intervention: 250 mg thrice daily oral tranexamic acid plus HQ 4% cream nightly
Number of subjects: 100

Group type: COMPARATOR
Intervention: HQ 4% cream only
Number of subjects: 100
Study: 25968575

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) after 8 weeks of chronic RT
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acute RE
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 8 weeks of RT
Number of subjects: 14
Study: 24199872

Group type: EXPERIMENTAL
Intervention: Clinical feeding evaluation with cervical auscultation (CFE + CA)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Clinical feeding evaluation only (CFE)
Number of subjects: 216
Study: 21388750

Group type: EXPERIMENTAL
Intervention: 0.5% betaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1% CLA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% betaine + 1% CLA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 19965324

Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide (Group 2, n=50, 10mg/ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intermittent furosemide (Group 1, n=50, 1mg‐3mg/kg)
Number of subjects: 100
Study: 17768273

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism rs6122429
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism rs2236196
Number of subjects: 316
Study: 15347371

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP, 100 microg Diskus, twice daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral montelukast (MON 10 mg, nocte)
Number of subjects: 36
Study: 11573668

Group type: EXPERIMENTAL
Intervention: Slow injection of 3 ml of 0.5% plain bupivacaine by infusion pump over 3 min (1 ml min(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fast injection of 3 ml of 0.5% plain bupivacaine by hand over 10 s (18 ml min(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Slow injection group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fast injection group
Number of subjects: 20
Study: 11041533

Group type: EXPERIMENTAL
Intervention: Zolpidem (ZPD, 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triazolam (TRZ, 0.25 mg)
Number of subjects: 0
Study: 8617150

Group type: EXPERIMENTAL
Intervention: Attention conditions with deviant stimuli (targets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ignore conditions with standard stimuli omitted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counting infrequently presented 'deviants' alone (standards omitted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipsilateral side detection task
Number of subjects: 0
Study: 1862903

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intramuscular morphine injections on demand
Number of subjects: 32
Study: 6137171

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naloxone 0.015 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30612114

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Traditional biomedical educational intervention
Number of subjects: 184
Study: 30100532

Group type: EXPERIMENTAL
Intervention: 80-Hz STN-DBS
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 130-Hz STN-DBS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 26344009

Group type: EXPERIMENTAL
Intervention: Treatment for GDM with diet, blood glucose monitoring, and insulin as needed.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Treatment for GDM with diet, blood glucose monitoring, and insulin as needed (nonobese women).
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care (control group, nonobese women).
Number of subjects: 95
Study: 24887209

Group type: EXPERIMENTAL
Intervention: ReNu MPS (solution 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AQuify MPS (solution 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comfort and dryness reporting
Number of subjects: 42
Study: 23057029

Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 11
Study: 19773417

Group type: EXPERIMENTAL
Intervention: High-dose daclizumab (first dose: 2 mg/kg) with low-dose cyclosporine (CsA), mycophenolate mofetil (MMF), and steroids
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard treatment (CsA, MMF, steroids)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: High-dose daclizumab
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 156
Study: 17921732

Group type: COMPARATOR
Intervention: CEOP-21 +/− rituximab
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: CEOP-14 +/− rituximab
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: CEOP-21/CEOP-14 with rituximab
Number of subjects: 217
Study: 16151461

Group type: COMPARATOR
Intervention: Folic acid (400 mug daily for 5 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: [6S]5‐methylTHF (equimolar amounts for 5 weeks)
Number of subjects: 24
Study: 12162937

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (AT) therapy
Number of subjects: 0
Study: 10402091

Group type: EXPERIMENTAL
Intervention: Modafinil treatment for 9 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Auditory and visual P300 testing
Number of subjects: 21
Study: 7560584

Group type: EXPERIMENTAL
Intervention: Compomer restorations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compomer liners
Number of subjects: 0
Study: 2147537

Group type: EXPERIMENTAL
Intervention: Amlodipine (0.4 to 45 micrograms/min/100 ml forearm tissue)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amlodipine (44.5 micrograms/min/100 ml) + Verapamil (40 micrograms/min/100 ml)
Number of subjects: 8
Study: 30168635

Group type: EXPERIMENTAL
Intervention: KCCQ score increase by ≥5 points
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: KCCQ score decrease by ≥5 points
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: KCCQ score change by <5 points
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: KCCQ score decline (per 5-point decline)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: KCCQ score increase (up to 8-point increase)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: KCCQ score increase beyond 8 points
Number of subjects: 2331
Study: 29339650

Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT) with a daily maintenance dose of 795 mg of peanut protein
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (historical)
Number of subjects: 22
Study: 27049273

Group type: EXPERIMENTAL
Intervention: Supraglottic jet oxygenation/ventilation (SJV)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Passive oxygen supply from regular nasal cannula (Control)
Number of subjects: 49
Study: 25270186

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 209

Group type: COMPARATOR
Intervention: Loxoprofen
Number of subjects: 209
Study: 22794212

Group type: EXPERIMENTAL
Intervention: Capasio
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capasio and MTA
Number of subjects: 0
Study: 20369614

Group type: EXPERIMENTAL
Intervention: Combined therapy with indapamide and verapamil retard
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combined therapy with indapamide and amlodipine
Number of subjects: 59
Study: 17535469

Group type: EXPERIMENTAL
Intervention: Positive frame valence
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Negative frame valence
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Procedural risk
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Goal frames
Number of subjects: 200
Study: 16298748

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study: 12094904

Group type: EXPERIMENTAL
Intervention: Nonverbal sensitivity training group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Behavioral placebo group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Patient symptomatology
Number of subjects: 91
Study: 10219575

Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg i.v. bolus at time of anesthesia)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Cefazolin (2 g at induction of anesthesia and 1 g every 6 h postoperatively, i.v. bolus)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 860

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 860
Study: 7832544

Group type: EXPERIMENTAL
Intervention: High-function (HF) group, n=23
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-function (LF) group, n=12
Number of subjects: 35
Study: 2401060

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary angioplasty
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Type A stenoses
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Type B1 stenoses
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Type B2 stenoses
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Type C stenoses
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus presence
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Modified ACC/AHA classification
Number of subjects: 350
Study: 468763

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 34
Study: 31142526

Group type: EXPERIMENTAL
Intervention: Full model (age, systolic blood pressure, Glasgow Coma Scale, heart rate, respiratory rate, type of injury)
Number of subjects: 23430

Group type: EXPERIMENTAL
Intervention: Simple model (age, systolic blood pressure, Glasgow Coma Scale)
Number of subjects: 23430

Group type: COMPARATOR
Intervention: CRASH-2 trial
Number of subjects: 23430

Group type: COMPARATOR
Intervention: Northern French Alps Trauma registry
Number of subjects: 23430
Study: 27754731

Group type: EXPERIMENTAL
Intervention: Tele‐intervention Model and Monitoring of Families of Drug Users (TMMFDU)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Usual Treatment (UT)
Number of subjects: 325
Study: 26049552

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study: 23768273

Group type: COMPARATOR
Intervention: Home physical therapy (HPT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manual therapy in conjunction with home physical therapy (MT-HPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between HPT and MT-HPT
Number of subjects: 40
Study: 20393694

Group type: EXPERIMENTAL
Intervention: Intra-operative periarticular injection with local anaesthetic and adrenaline plus triamcinolone acetonide
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intra-operative periarticular injection with local anaesthetic and adrenaline
Number of subjects: 83
Study: 19143771

Group type: EXPERIMENTAL
Intervention: Carbachol (3 microg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15684287

Group type: EXPERIMENTAL
Intervention: bosentan
Number of subjects: 169
Study: 12730341

Group type: EXPERIMENTAL
Intervention: Neck Pressure (NP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Neck Suction (NS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carotid baroreflex (CBR) function
Number of subjects: 8
Study: 10589859

Group type: EXPERIMENTAL
Intervention: 70% carbohydrate (CHO) meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: 90% fat meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heparin administration (1000 U, 500 U, and 500 U before exercise)
Number of subjects: 6

Group type: COMPARATOR
Intervention: CHO trial
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fat trial
Number of subjects: 6
Study: 8948505

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (Dolner 40 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elastase (Elaszym 1800 U)
Number of subjects: 0
Study: 1753158

Group type: EXPERIMENTAL
Intervention: 5F coronary catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6F coronary catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8F coronary catheters
Number of subjects: 0
Study: 6805451

Group type: EXPERIMENTAL
Intervention: Massive-dose vitamin A therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction of protein-energy malnutrition (PEM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated massive vitamin A therapy
Number of subjects: 0
Study: 30359789

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 184

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 184
Study: 28950849

Group type: EXPERIMENTAL
Intervention: Bacteriophage (Pyo bacteriophage) solution for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo solution for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic treatment according to sensitivity pattern for 7 days
Number of subjects: 0
Study: 26308643

Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 130

Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 130
Study: 23179499

Group type: EXPERIMENTAL
Intervention: Self-reported urinary incontinence
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Symptomatic pelvic organ prolapse
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Anatomical pelvic organ prolapse stage II-IV
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Prolapse questionnaire validity
Number of subjects: 395
Study: 21590473

Group type: EXPERIMENTAL
Intervention: Oral clonidine 0.2 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 18356448

Group type: EXPERIMENTAL
Intervention: 450 mg I/kg of body weight
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 525 mg I/kg of body weight
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 600 mg I/kg of body weight
Number of subjects: 135
Study: 16298373

Group type: EXPERIMENTAL
Intervention: A1 beta-casein diet
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: A2 beta-casein diet
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of A1 and A2 diets
Number of subjects: 62
Study: 14700556

Group type: EXPERIMENTAL
Intervention: Pegvisomant (median dose 15 mg/day, range 10-40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH receptor blockade (not specified)
Number of subjects: 16
Study: 11426352

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9413377

Group type: EXPERIMENTAL
Intervention: Thrombectomy combined with a temporary arteriovenous fistula and anticoagulation (surgical group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional anticoagulation treatment (medical group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 8435902

Group type: EXPERIMENTAL
Intervention: Low dose FSH (37.5 units daily, increased in 37.5 unit increments)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Conventional dose FSH (75 units daily, increased in 75 unit increments)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 13
Study: 3630923

Group type: EXPERIMENTAL
Intervention: Nadolol (0.01, 0.02, and 0.04 mg/kg, maximum total dosage 10 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29264967

Group type: EXPERIMENTAL
Intervention: Probiotic tablets containing Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Probiotic tablets
Number of subjects: 47